Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | PACS | ECG |
|---|---|---|
| Price | $42.81 | $132.74 |
| Change today | ▲ 0.23% | ▲ 5.21% |
| Market cap | $6.78B | $6.78B |
| Return, 3 months | -2.7% | -1.2% |
| Return, year to date | +11.5% | +55.1% |
| Return, 1 year | +221.9% | +60.7% |
| P/E (TTM) | 25.0 | 26.7 |
| P/B | 6.1 | 8.8 |
| P/E percentile vs own 5y | 48th | 59th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +9.1% | +33.7% |
| Net profit growth (YoY) | +49.8% | +58.8% |
| Gross margin | 16.6% | 13.0% |
| Operating margin | 7.4% | 7.8% |
| Net margin | 4.8% | 6.0% |
| Return on equity | 28.1% | 39.5% |
| Analyst target vs. price | +35.5% | +32.6% |
| Analyst buy share | 100% | 83% |
| RSI (14) | 51 | 68 |
| 30-day volatility | 32.1% | 39.4% |
| Max drawdown, 1 year | -27.9% | -35.5% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
